干扰素α2b联合拉米夫定治疗慢性乙型肝炎患者血清HBeAg阴转和肝功能的变化*

doi:10.3969/j.issn.1672-5069.2016.01.022

Abstract

Nie Shangyan, Song Huanhuan, Wang Min, et al. Combination of interferon-α2b and lamivudine in the treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 86-87.

References

[1] 窦晓光. 丙氨酸转氨酶正常的慢性乙型肝炎病毒感染人群抗病毒治疗策略. 中国实用内科杂志,2013,33（6）:454-456.
[2] Hao R,Xiang K,Peng Y,et al. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. Infect Genet Evol,2015,48（15）:166-175.
[3] 裴冬萍.乙型肝炎肝硬化抗病毒治疗3年病情转归分析. 现代预防医学,2013,40（8）：1596-1597.
[4] 申婷,游晶,范晶华,等. 慢性乙型肝炎抗病毒治疗研究进展. 实用医学杂志,2014,30（3）：339-341.
[5] 陈成伟,陈从新,陈士俊,等. 核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理. 中国实用内科杂志,2013,33（1）：82-91.
[6] Keshvari M,Alavian SM,Sharafi H. Comparison of serum hepatitis B virus DNA and HBsAg levels between HBeAg-negative and HBeAg-positive chronic hepatitis B patients. J Microbiol,2015,8（3）：21-44.
[7] 周友乾,尹凤鸣,冯经华,等. 丙型肝炎病毒载量与基因型和抗病毒疗效的关系研究. 实用肝脏病杂志,2011,14（5）：340-343.
[8] 苏荣,罗娜,杨延斌,等. 3种临床类型乙型肝炎患者HBeAg、HBV DNA及ALT的差异分析. 现代预防医学,2013,40（21）：4054-4056.
[9] 黎明,吴锦瑜,徐冠军,等. 拉米夫定与阿德福韦酯联合治疗应答不佳的慢性乙型肝炎患者的抗病毒治疗. 南方医科大学学报,2013,33（12）：1823-1826.
[10] 陈勇良,李振燕,姚春甫,等. TGF-β1、PDGF-BB与慢性乙型肝炎肝纤维化相关性研究. 实用肝脏病杂志,2010,13（2）：100-103.
[11] 李延玲,翟玉峰,张怀宏. 抗病毒疗法对慢性乙型肝炎患者肝癌发病的影响. 世界华人消化杂志,2014,35（22）：5516-5520.
[12] Dammermann W,Bentzien F,Stiel EM,et al. Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic hepatitis B?patients. J Transl Med,2015,13（1）：157-182.
[13] 钮志林,朱翔,沈伟强,等. 干扰素对慢性乙型肝炎患者肝细胞内HBV cccDNA、血清HBsAg、HBV DNA的影响研究. 中华医院感染学杂志,2014,24（4）：792-795.
[14] 刘同燕,张龙跃,李月荣,等. 干扰素α与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎前瞻性队列观察. 山东大学学报（医学版）,2014,52（6）：72-77.
[15] 张晓培,秦爱兰,张玉婷,等. 聚乙二醇干扰素治疗33例慢性乙型肝炎的疗效. 江苏医药,2014,40（11）：1277-1279.

Combination of interferon-α2b and lamivudine in the treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.